ROBERT L. DOW Medicinal and Synthetic Chemistry

EDUCATION: PhD-Synthetic Organic Chemistry, Harvard University with David Evans.

EXPERIENCE: 1985-2021 Oncology, Obesity, Atherosclerosis, Diabetes, Cardiovascular and Rare Diseases Medicinal Chemistry.

EXPERTISE: Drug Design and Synthesis with Expertise in Structure-Based Drug Design, DMPK and Drug Safety, Research Project Leader for Multiple Cross-Disciplinary Drug Discovery Teams, Extensive People Manager Experience.  Co-Inventor of 14 Clinical Candidates and over 100 Scientific Publications and Patents.

BIO

Bob has 35 years of experience as a medicinal chemist at Pfizer. He performed undergraduate research with Michael Doyle at Hope College and went on to earn his Ph.D. in synthetic organic chemistry with David Evans at California Institute of Technology/Harvard University.  While at Pfizer, he has been involved in multiple discovery areas, including oncology, obesity, atherosclerosis, diabetes, cardiovascular and multiple rare disease indications. His contributions have led to the discovery of 14 agents that have entered clinical trials, including the liver-selective ACC inhibitor clesacostat, which is currently in Ph 2 for the treatment of NASH. He was selected to be the Research Project Leader for multiple Pfizer programs, with cross-disciplinary responsibility for driving teams to clinical candidate identification.  Two external research collaborations proposed by him were funded by Pfizer; the first was with Professor David Stern with the Department of Physiology, Yale University and the other with Professor M. G. Finn at Scripps. Bob received the Upjohn Medal in 2007 for his drug discovery leadership role leading to a clinical candidate for the DGAT inhibitor program. He also served as Cardiovascular and Metabolic Diseases Section Editor for Annual Reports in Medicinal Chemistry/Medicinal Chemistry Reviews (2012-2017) and has over 100 publications/patents.